Bright Green has achieved several key milestones throughout the Quarter significantly advancing progress against its strategic plan, including a historic DEA Federal Registration and License Approval.

Continued marketing of its fundamental capital raise of $500+ million utilizing the U.S. Citizen & Immigration Services EB-5 program.

Completed a $3.5 million private placement for greenhouse improvements and general corporate expenses.

GRANTS, N.M., August  17, 2023 — Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or “the Company”), one of few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications, and affiliated export, reported financial results for the quarter ended June 30, 2023.

“This quarter, Bright Green was focused on several key operational and strategic milestones revolving around the receipt of our license from DEA, further outfitting of the greenhouse, and marketing of the EB-5 capital raising program said Terry Rafih, Executive Chairman. “We are focused on making strategic decisions and realizing the full potential of the opportunity and maximizing shareholder value with minimum further dilution.”

Strategic Highlights for Second Quarter 2023

  • The DEA completed their on-site audit and assessment of our facilities in March 2022, which culminated in Bright Green being registered as a bulk manufacturer by the DEA and issued our Federal Registration and License Approval on May 01, 2023.
  • The Company focused on the marketing of its previously announced plans to raise $500 million utilizing the USCIS EB-5 Program to accelerate its growth strategy and generate significant capital for use in its greenhouse construction and operations in Grants, New Mexico.
    • The EB-5 Program, which President Biden reauthorized in 2022, is an innovative vehicle for spurring investment and job creation in rural communities. Bright Green’s participation will add significant value to the region, while also generating the capital needed for its commercial and business initiatives.
    • To date, Bright Green has sold 44,010 shares of common stock at $39.99 per share, receiving proceeds of $1.76 million. The Company is working diligently to finalize agreements with prospective EB-5 investors.
    • The Company announced its expectations of minimum debt and minimum share dilution to execute our business plan and be the lowest cost, and highest quality producer of pharmaceutical cannabis in both dried flower and extract based applications for sales domestically and export to the European markets.
  • The Company outlined its plans to move forward with its acquisition of Alterola, following the completion of its initial 25% acquisition during the quarter. The Company is in active discussions with Alterola management.
  • Bright Green entered into a Securities Purchase Agreement with an institutional and accredited investor for the sale by the Company of (i) 3,684,210 shares of Common Stock and (ii) warrants to purchase up to an aggregate of 3,684,210 shares of Common Stock, in a private placement offering at a purchase price of $0.95 per share and accompanying warrant.

Financial Highlights for Second Quarter 2023

  • The Company recorded no revenues for the quarter, as it continues to construct facilities for its cannabis cultivation, research, and distribution, as well as obtaining necessary registration and quota approvals.
  • Total operating expenses of $3.0 million, down from $19.2 million in the same quarter of 2022, in line with expectations as the second quarter of 2022 includes significant costs associated with the Company’s direct listing on Nasdaq. Of the $3.0 million in operating expenses, $1.4 million corresponds to equity-based compensation to officers, contractors, and professional services providers.
  • Net loss of $3.0 million, in line with expectations.
  • Basic and diluted loss per share of $0.02 for the quarter.

Balance Sheet and Capital Allocation

  • As of June 30, 2023, the Company had cash of $507,445, consistent with its cash position of $414,574 at December 31, 2022.
  • Total liquidity of $11.9 million, including the remaining balance on the credit facility of approximately $11.4 million.
  • During the second quarter of 2023, the Company raised $3.1 million through the issuance of common stock and accompanying warrants to purchase shares of common stock from the Company’s private placement offering.

Bright Green’s balance sheet and statement of operations are provided below. Additional information is included in the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2023, which can be accessed at:

About Bright Green

Bright Green is one of the very few companies eligible for authorization by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications, and affiliated export. Our registration by the U.S. Drug Enforcement Administration gives us the opportunity to advance our vision of improving quality of life through the opportunities presented by cannabis-derived therapies. To learn more, visit